CD30-Specific CAR T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma

Natalie S. Grover, MD, assistant professor at the University of North Carolina Chapel Hill, discusses the potential role of CD30-specific chimeric antigen receptor (CAR) T cells in patients with relapsed/refractory Hodgkin lymphoma.

While the majority of patients treated in the first-line setting will do well, there is still a portion of patients that have refractory disease, Grover says. While there are great treatment options available, including brentuximab vedotin (Adcetris), and checkpoint inhibitors, these are still not curative.